Melflufen (INN melphalan flufenamide) is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload.
Melflufen is an investigational drug and is not approved for commercial use.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
Oncopeptides held a virtual Capital Markets Day for investors, analysts and journalists on November 30, 2020. The CMD was webcasted live and recorded, accessible through the link below.
Marty J Duvall presented at Jefferies London Health Care Conference, Wednesday November 18, 2020. The webcast was recorded.